Protective effect of SGL5213, a potent intestinal sodium–glucose cotransporter 1 inhibitor, in nonalcoholic fatty liver disease in mice

Protective effect of SGL5213, a potent intestinal sodium–glucose cotransporter 1 inhibitor, in nonalcoholic fatty liver disease in mice

Background: Nonalcoholic fatty liver disease (NAFLD) is the most common chronic disease. SGL5213, which is minimally absorbed and is restricted to the intestinal tract, is a potent intestinal sodium–glucose cotransporter 1 (SGLT1) inhibitor. In this study, we investigated the protective effect of SG...

Full description

Bibliographic Details
Main Authors: Yasushi Honda, Anna Ozaki, Michihiro Iwaki, Takashi Kobayashi, Asako Nogami, Takaomi Kessoku, Yuji Ogawa, Wataru Tomeno, Kento Imajo, Masato Yoneda, Satoru Saito, Yoji Nagashima, Atsushi Nakajima
Format: Article
Language:English
Published: Elsevier 2021-10-01
Series:Journal of Pharmacological Sciences
Subjects:
NAFLD
NASH
SGL5213
SGLT1 inhibitor
Miglitol
Online Access:http://www.sciencedirect.com/science/article/pii/S1347861321000694

Internet

http://www.sciencedirect.com/science/article/pii/S1347861321000694

Similar Items